MedTrace Logo

Transperineal Ultrasound as a Biofeedback Tool for Pelvic Floor Muscle Therapy in Postpartum Patients

NCT07065708 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2025-07-15

No results posted yet for this study

Summary

Regular and effective pelvic floor muscle exercises after vaginal birth are crucial in reducing the risk of pelvic floor disorders in women. Pelvic floor muscle exercises are generally encouraged by healthcare providers to their patients after birth. However, it is often difficult to confirm whether a patient is performing pelvic floor muscle contractions correctly. A supervised pelvic floor physiotherapy session allows a professional to assess the pelvic floor and give their verbal feedback to patients. However even in this setting, patient's are reliant on the physiotherapist and have no way to assess their own performance. The 'biofeedback approach' allows for the clinician and patient to visually assess and modify their performance and can potentially allow for more effective therapy and better engagement. Transperineal ultrasonography is a widely available, safe and non-invasive biofeedback tool that can used at the bedside in order to assess pelvic floor muscle contractions. Our aim is to assess if using transperineal ultrasound can enhance the ability of postpartum patients to perform effective pelvic floor muscle therapy.

Conditions

  • Pelvic Floor Muscle Training
  • Transperineal Ultrasound
  • Biofeedback Therapy
  • Postpartum
  • Pelvic Floor Disorder
  • Pelvic Floor Muscle Exercise
  • Pelvic Floor, Obstetric
  • Pelvic Floor Dysfunction
  • Pelvic Floor Health After Childbirth
  • Physiotherapy
  • Physiotherapy Specialty

Interventions

DIAGNOSTIC_TEST

Visual biofeedback using transperineal ultrasound

Transperineal ultrasound with visual biofeedback

DIAGNOSTIC_TEST

Transperineal ultrasound without visual biofeedback

Transperineal ultrasound without visual biofeedback

Sponsors & Collaborators

  • Singapore General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-20
Primary Completion
2026-06-30
Completion
2026-09-30

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07065708 on ClinicalTrials.gov